Explore an Innovative IPF Trial

Promising research suggests improved clinical outcomes in IPF patients treated with antibiotics.

The CleanUP IPF Trial – the largest National Institutes of Health (NIH) sponsored trial in IPF – is investigating antibiotics in 500 patient participants and is now fully enrolled. The trial will continue for three years, and once it’s completed, researchers will utilize new technologies and platforms to analyze the collected data and biological samples.

“We have an opportunity to lead the investigative community in a new format for study design while providing patients a cost effective, simple and well tolerated therapeutic approach that may not only improve outcomes but also quality of life.”

– Dr. Fernando Martinez, MD, one of the lead investigators for CleanUP IPF

Participating Medical Centers

Alabama
  • University of Alabama at Birmingham
Arizona
  • University of Arizona-Tucson

California
  • University of California – Davis
  • Stanford Medical Center
Illinois
  • Loyola University Chicago
  • Northwestern Memorial Hospital
  • University of Chicago Medical Center
Massachusetts
  • Massachusetts General Hospital
  • Brigham & Women’s Hospital
  • Beth Israel Deaconess Medical Center
Michigan
  • Spectrum Health Pulmonary
  • University of Michigan
Minnesota
  • Mayo Clinic
  • University of Minnesota
New Hampshire
  • Dartmouth-Hitchcock Medical Center
New York
  • Albany Medical College
  • Columbia University
  • University of Rochester
    Medical Center
  • Weill Cornell Medicine
Ohio
  • University of Cincinnati Medical Center
  • Cleveland Clinic
  • OSU Wexner Medical Center
Pennsylvania
  • Penn State Hershey Medical Center
  • Temple University
Tennessee
  • Vanderbilt University
Texas
  • University of Texas Health Science Center San Antonio
Utah
  • University of Utah Health Sciences – Lung Health Clinical Research
Virginia
  • UVA Medical Center
  • INOVA
Washington
  • University of Washington Medical Center

The Cleanup IPF trial is possible thanks to the leadership and foresight of the investigators and the financial support of the National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Partners, Veracyte and our IPF Foundation.

“If micro-organisms are triggering and/or sustaining the disease and we are able to figure this out, then a cure should be in sight.”

– Dr. Jerry Eu, Former Program Director, Immunology/Fibrosis at the NIH (2016)

The CleanUP IPF Trial is Curve Jumping!